Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate

Biomaterials
Elisabetta CenniNicola Baldini

Abstract

Nanoparticles made of a conjugate of poly(D,L-lactide-co-glycolide) with alendronate (PLGA-ALE NPs), were prepared by emulsion/solvent evaporation technique. The conjugation yield, determined by MALDI TOF analysis, was 30-35%. PLGA-ALE NPs size, evaluated by photon correlation spectroscopy, was 198.7+/-0.2 nm. Haemocompatibility studies using different concentrations of PLGA-ALE NPs did not show any significant effect on haemolysis, leukocyte number, platelet activation, APTT and complement consumption, in comparison with blood incubated with phosphate buffered saline (PBS). A significant reduction of the prothrombin activity was demonstrated after incubation with 560 microg/ml of PLGA-ALE NPs; a significant increase was observed at the highest dilutions. The viability of human umbilical vein endothelial cells and bone marrow stromal cells (BMSC), evaluated through the neutral red test, was not affected by PLGA-ALE NPs. There were no significant differences in cell-associated alkaline phosphatase between BMSC incubated with PLGA-ALE NP- and PBS-added media. These results demonstrated that PLGA-ALE NPs had an acceptable degree of blood compatibility and were not cytotoxic; therefore, they may be considered suitable for intraveno...Continue Reading

References

Jan 1, 1974·Oral Surgery, Oral Medicine, and Oral Pathology·D E CutrightW R Posey
Oct 6, 2000·Journal of Medicinal Chemistry·A EzraG Golomb
Jun 8, 2002·Biotechnology Progress·Hasan Uludag, Jennifer Yang
Sep 18, 2003·Bioconjugate Chemistry·Dong WangJindrich Kopecek
Feb 18, 2004·Current Medicinal Chemistry·Si-Shen FengGuofeng Huang
May 4, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·María J Blanco-PríetoBruno Gander
Jan 12, 2005·Colloids and Surfaces. B, Biointerfaces·D KimT Morey
May 7, 2005·Advanced Drug Delivery Reviews·Dong WangJindrich Kopecek
Sep 15, 2005·British Journal of Pharmacology·Anna RadomskiMarek W Radomski
Oct 4, 2005·Molecular Immunology·Carolina Salvador-MoralesRobert B Sim
Nov 18, 2005·International Journal of Pharmaceutics·E LeoA Dalpiaz
Feb 21, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·A LayreR Gref
May 13, 2006·Journal of Biomaterials Science. Polymer Edition·Carlos E Astete, Cristina M Sabliov
Jun 17, 2006·Journal of Biomedical Materials Research. Part a·A VonarbourgJ P Benoit
Aug 5, 2006·International Journal of Pharmaceutics·T MusumeciG Puglisi
Oct 20, 2006·Journal of Nanoscience and Nanotechnology·T MusumeciG Puglisi
Oct 20, 2006·Journal of Nanoscience and Nanotechnology·Einat Cohen-SelaJianchuan Gao
May 15, 2007·Advanced Drug Delivery Reviews·Soo-Hong Lee, Heungsoo Shin
Jul 4, 2007·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Gustavo Duque, Daniel Rivas
Jul 14, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Sung-Wook Choi, Jung-Hyun Kim

❮ Previous
Next ❯

Citations

Mar 17, 2011·Physical Chemistry Chemical Physics : PCCP·Farah BenyettouLaurence Motte
Oct 21, 2009·Nanomedicine·Xue LiMarek W Radomski
Jun 15, 2013·Pharmaceutical Research·Zhe WangXiaoyuan Chen
Jan 11, 2014·Drug Delivery·Mohammad FazilJaved Ali
May 10, 2013·Expert Opinion on Drug Delivery·Khaled Mohamed HosnyRana Tariq Al-Abdali
Feb 12, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Elisabeth V GigerJean-Christophe Leroux
Feb 5, 2013·International Journal of Pharmaceutics·K MiladiA Elaissari
Jan 3, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Natalia R KuznetsovaChristian Grandfils
Feb 10, 2012·Advanced Drug Delivery Reviews·Stewart A Low, Jindřich Kopeček
Oct 22, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Tessa LuhmannLorenz Meinel
Apr 24, 2010·International Journal of Pharmaceutics·Krishna Hari BhandariMichael R Doschak
May 8, 2010·Colloids and Surfaces. B, Biointerfaces·Nany GulatiVeena Koul
Nov 27, 2015·Nanomedicine·Mohammad Mahdi Hasani-SadrabadiKarl I Jacob
Oct 21, 2015·Advanced Drug Delivery Reviews·Lisa E ColeRyan K Roeder
Oct 5, 2010·British Journal of Pharmacology·Cf AlvesMh Napimoga
Apr 7, 2016·International Journal of Pharmaceutics·Muhammad ImranImdad Ali
Apr 14, 2016·Physical Chemistry Chemical Physics : PCCP·Zelai HeYourong Duan
Nov 28, 2012·Nanomedicine : Nanotechnology, Biology, and Medicine·Anil WaghBenedict Law
Dec 16, 2011·Chemical Society Reviews·Shahriar SharifiMorteza Mahmoudi
May 4, 2016·Expert Opinion on Drug Delivery·Brenda Armendáriz-BarragánAbdelhamid Elaissari
Jun 4, 2016·Journal of Tissue Engineering and Regenerative Medicine·Yao-Hsien WangMei-Ling Ho
Nov 10, 2016·International Journal of Pharmaceutics·Waisudin BadriAbdelhamid Elaissari
Nov 9, 2016·Artificial Cells, Nanomedicine, and Biotechnology·Muhammad ImranWaqas Nawaz
Aug 27, 2016·Nanomedicine : Nanotechnology, Biology, and Medicine·Erica J CarboneKevin W-H Lo
Feb 6, 2017·Drug Development and Industrial Pharmacy·Shafi UllahFarid Ahmed
Jan 1, 2012·Journal of Functional Biomaterials·Rosario PignatelloFrancesco Castelli
Jul 26, 2011·Journal of Biomaterials Science. Polymer Edition·Elisabetta CenniNicola Baldini
Jan 13, 2017·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Jan Simak, Silvia De Paoli
Sep 19, 2020·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Krzysztof MilewskiPaweł E Buszman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.